Immunodominant deters the response to other tumor antigens thereby favoring escape: prevention by vaccination with tumor variants selected with cloned cytolytic T cellsin vitro-Reference-Cited by-同舟云学术

Immunodominant deters the response to other tumor antigens thereby favoring escape: prevention by vaccination with tumor variants selected with cloned cytolytic T cellsin vitro

Published:1996-05 Issue:5 Volume:47 Page:399-407
ISSN:0001-2815
Container-title:Tissue Antigens
language:en
Short-container-title:

Author:

Waes C.,Monach P. A.,Urban J. L.,Wortzel R. D.,Schreiber H.

Publisher

Wiley

Subject

Genetics,Biochemistry,Immunology,General Medicine,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1399-0039.1996.tb02575.x/fullpdf

Reference33 articles.

1. Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells;Ward;J Exp Med,1989

2. Major histocompatibility complex class I and unique antigen expression by murine tumors that escaped from CD8+ T-cell-dependent surveillance;Ward;Cancer Res,1990

3. Mechanisms of syngeneic tumor rejection: susceptibility of host-selected progressor variants to various immunological effector cells;Urban;J Exp Med,1982

4. Highly malignant tumor variants retain tumor-specific antigens recognized by helper T cells;Waes;J Exp Med,1986

5. A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target;Seung;J Exp Med,1993

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modeling immunodominance in the B-cell response to viral infection;Mathematics and Mechanics of Complex Systems;2023-11-12

2. Mechanisms of resistance to T cell‐based immunotherapy in head and neck cancer;Head & Neck;2020-04-10

3. Targeted cancer immunotherapy with genetically engineered oncolytic Salmonella typhimurium;Cancer Letters;2020-01

4. Improving responses to immunotherapy in head and neck squamous cell carcinoma;Improving the Therapeutic Ratio in Head and Neck Cancer;2020

5. How patients with an intact immune system develop head and neck cancer;Oral Oncology;2019-05